<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278872</url>
  </required_header>
  <id_info>
    <org_study_id>SJX-653-006</org_study_id>
    <nct_id>NCT04278872</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</brief_title>
  <official_title>A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sojournix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sojournix, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily&#xD;
      SJX-653 in postmenopausal women with moderate to severe VMS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision to terminate the study as anticipated target profile (confirmation of the selected&#xD;
    dose of SJX-653 as safe and efficacious for further development for the treatment of moderate&#xD;
    to severe vasomotor symptoms in postmenopausal women) not met&#xD;
  </why_stopped>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Actual">April 7, 2021</completion_date>
  <primary_completion_date type="Actual">February 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in average daily frequency of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the severity of moderate to severe VMS from Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change and percent change of parameters of VMS frequency and severity by study week</measure>
    <time_frame>Baseline up to Week 6</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Insomnia Severity Index (ISI)</measure>
    <time_frame>Baseline up to Week 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Hot Flash Related Daily Interference Scale (HFRDIS)</measure>
    <time_frame>Baseline up to Week 4</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>SJX-653</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SJX-653</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJX-653</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>SJX-653</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed a consent form before Screening procedures begin.&#xD;
&#xD;
          2. Be a postmenopausal female, 40 to 65 years of age (inclusive) at the Screening Visit,&#xD;
             defined as:&#xD;
&#xD;
               1. Spontaneous amenorrhea for at least 12 months, OR&#xD;
&#xD;
               2. 6 months of spontaneous amenorrhea with serum FSH levels &gt;40 milli-International&#xD;
                  unit (mIU/mL), OR&#xD;
&#xD;
               3. 6 weeks past a postsurgical bilateral oophorectomy with or without hysterectomy.&#xD;
&#xD;
             All postmenopausal woman (PMW) must have a serum follicle stimulating hormone (FSH)&#xD;
             &gt;40 mIU/mL at Screening.&#xD;
&#xD;
          3. Have an average of at least 7 moderate to severe VMS per day at Baseline. The&#xD;
             following definitions for severity are used:&#xD;
&#xD;
               1. Mild: Sensation of heat without sweating/damping; if at night, do not wake up but&#xD;
                  later notice damp sheets or clothing.&#xD;
&#xD;
               2. Moderate: Sensation of heat with sweating/dampness, but able to continue&#xD;
                  activity; if at night, wake up because hot and/or sweating, but no action is&#xD;
                  necessary other than rearranging the bed sheets.&#xD;
&#xD;
               3. Severe: Sensation of heat with sweating causing disruption of current activity;&#xD;
                  if at night, wake up hot and sweating and need to take action (eg, removing layer&#xD;
                  of clothes, open the window, or get out of bed).&#xD;
&#xD;
          4. Have a body mass index between 18 and 35 kg/m2, inclusive.&#xD;
&#xD;
          5. For subjects 50-65 years old, have documentation (written or electronic report) of a&#xD;
             satisfactory mammogram result at Screening within applicable intervals stated in local&#xD;
             breast cancer screening guidelines. Subjects 40-49 years old require a mammogram&#xD;
             within the same intervals.&#xD;
&#xD;
          6. Have documentation (written or electronic report) of a normal Pap smear (or equivalent&#xD;
             cervical cytology) ) in combination with Human Papilloma virus (HPV) testing, or a Pap&#xD;
             smear of no clinical significance in the opinion of the Investigator, at Screening&#xD;
             within applicable intervals stated in local cervical cancer prevention guidelines.&#xD;
&#xD;
          7. Have an endometrial thickness ≤4 mm by transvaginal ultrasound at Screening.&#xD;
&#xD;
          8. Be willing to undergo an endometrial biopsy if they have unexplained bleeding during&#xD;
             the study or endometrial thickness &gt;4 mm at the EOT visit. An endometrial biopsy is&#xD;
             not required for subjects who have had a partial (supracervical) or full hysterectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have clinically significant history or evidence of poorly controlled cardiovascular,&#xD;
             respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological,&#xD;
             or psychiatric disorder(s) as determined by the Investigator or have any medical&#xD;
             condition that requires chronic medication and that in the Investigator's opinion,&#xD;
             would make subjects unsuitable for participation in the study.&#xD;
&#xD;
          2. Have manifest or suspected active COVID-19 infection. Have tested positive for&#xD;
             presence of SARS-CoV-2 based on a RT-PCR or other validated test; or have clinical&#xD;
             symptoms suggestive of COVID-19 infection; or have to comply with quarantine&#xD;
             requirements per local Public Health directive.&#xD;
&#xD;
          3. Have a history of diagnosis of major depressive disorder in the 3 years prior to&#xD;
             Screening, or are on any antidepressant, anxiolytic or antipsychotic treatment.&#xD;
             Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine&#xD;
             reuptake inhibitors (SNRIs) treatment for mild depression and/or mild anxiety is&#xD;
             allowed provided medication is stable and well-tolerated in the 3 months prior to the&#xD;
             Screening Visit and does not change during study participation.&#xD;
&#xD;
          4. Have a history of suicide ideation or attempt in the past 3 years.&#xD;
&#xD;
          5. Have a history of a sleep disorder other than insomnia due to VMS (eg, narcolepsy,&#xD;
             sleep apnea, restless leg syndrome).&#xD;
&#xD;
          6. Have clinical or biochemical evidence of active hepatitis or other significant hepatic&#xD;
             or biliary disease (eg, chronic hepatitis, cirrhosis, autoimmune hepatitis, primary&#xD;
             biliary cholangitis, primary sclerosing cholangitis, nonalcoholic steatohepatitis,&#xD;
             nonalcoholic fatty liver disease, or hereditary liver disease).&#xD;
&#xD;
          7. Have any abnormal liver function tests at Screening or an estimated glomerular&#xD;
             filtration rate (eGFR) &lt;60 mL/min/1.73 m2 (CKD-EPI 2009 calculation; Levey et al&#xD;
             2009).&#xD;
&#xD;
          8. Have tested positive for human immunodeficiency virus, hepatitis B, C or E at&#xD;
             Screening.&#xD;
&#xD;
          9. Have any gastrointestinal, liver, kidney or other disorder that would significantly&#xD;
             interfere with the absorption, distribution, metabolism, or excretion (ADME) of drugs&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
         10. Have a history of alcohol abuse or a history of substance abuse.&#xD;
&#xD;
         11. Smoking &gt;10 cigarettes per day.&#xD;
&#xD;
         12. Regularly working night shifts.&#xD;
&#xD;
         13. Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, based on&#xD;
             the median of a total of 4 to 6 readings, from 2 to 3 readings taken on 2 diﬀerent&#xD;
             occasions.&#xD;
&#xD;
         14. Have clinically significant abnormal ECG or QT interval prolongation (corrected for&#xD;
             heart rate using Fridericia formula [QTcF] prolongation &gt;470 ms) at Screening.&#xD;
&#xD;
         15. Have a history of endometrial hyperplasia or uterine/endometrial cancer.&#xD;
&#xD;
         16. Have current unexplained uterine bleeding.&#xD;
&#xD;
         17. Have a history of cancer prior to Screening (other than local, treated basal cell or&#xD;
             squamous cell carcinoma).&#xD;
&#xD;
         18. Have any significant illness requiring hospitalization or emergency treatment within 4&#xD;
             weeks prior to the Screening Visit or during the Screening or Run-in Periods, and as&#xD;
             determined by the Investigator.&#xD;
&#xD;
         19. Are pregnant or lactating.&#xD;
&#xD;
         20. Have used hormonal treatments within defined periods of time prior to the start of the&#xD;
             Run-in Period. Washout times dependent on treatment.&#xD;
&#xD;
         21. Are taking any nonhormonal medication for treatment of VMS in the 8-week period prior&#xD;
             to the start of the Run-in Period.&#xD;
&#xD;
         22. Have used herbal supplements or over-the-counter (OTC) medications for treatment of&#xD;
             VMS 8 weeks prior to the start of the Run in Period. Any other herbal supplements or&#xD;
             OTC supplements that could interfere with the study objectives require a 28-day&#xD;
             wash-out period prior to the start of the Run-in Period.&#xD;
&#xD;
         23. Are taking any antiestrogens, selective estrogen receptor modulators, or aromatase&#xD;
             inhibitors.&#xD;
&#xD;
         24. Are taking any antigonadotropin medication.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sojournix, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sojournix Site #202</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #204</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #201</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #308</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #309</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #304</name>
      <address>
        <city>Bernburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #301</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #306</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #305</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #401</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #402</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #403</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #404</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #405</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #406</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #108</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #111</name>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #104</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #112</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #110</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #105</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sojournix Site #107</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 17, 2021</submitted>
    <returned>September 13, 2021</returned>
    <submitted>October 1, 2021</submitted>
    <returned>October 28, 2021</returned>
    <submitted>November 12, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

